ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency https://www.globenewswire.com/news-release/2022/05/20/2447753/0/en/ClearPoint-Neuro-Congratulates-Partner-PTC-Therapeutics-on-Receiving-Positive-CHMP-Opinion-for-Gene-Therapy-to-Treat-AADC-Deficiency.html First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint’s SmartFlow® Cannula

https://www.fool.com/earnings/call-transcripts/2022/05/11/clearpoint-neuro-inc-clpt-q1-2022-earnings-call-tr/

ClearPoint Neuro Reports First Quarter 2022 Results https://www.globenewswire.com/news-release/2022/05/11/2441245/25687/en/ClearPoint-Neuro-Reports-First-Quarter-2022-Results.html

https://www.globenewswire.com/news-release/2022/05/03/2435061/25687/en/ClearPoint-Neuro-and-Higgs-Boson-Health-Announce-Collaboration.html

ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1 https://www.globenewswire.com/news-release/2022/04/28/2431949/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-of-the-SmartFrame-Array-Version-1-1.html Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room

ClearPoint Neuro Expands Software License and Research Agreement with Philips to Power Expansion of the ClearPoint Platform into the Operating Room https://www.globenewswire.com/news-release/2022/04/27/2430700/25687/en/ClearPoint-Neuro-Expands-Software-License-and-Research-Agreement-with-Philips-to-Power-Expansion-of-the-ClearPoint-Platform-into-the-Operating-Room.html

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results https://finance.yahoo.com/news/clearpoint-neuro-reports-fourth-quarter-210700519.html ClearPoint Neuro GAAP EPS of -$0.69 misses by $0.01, revenue of $16.3M in-line https://seekingalpha.com/news/3808108-clearpoint-neuro-gaap-eps-of-0_69-misses-0_01-revenue-of-16_3m-in-line ClearPoint Neuro press release (NASDAQ:CLPT): FY GAAP EPS of -$0.69 misses by $0.01. Revenue of $16.3M (+27.0% Y/Y) in-line.

ClearPoint Neuro Reports Third Quarter 2021 Results https://www.globenewswire.com/news-release/2021/11/09/2330872/25687/en/ClearPoint-Neuro-Reports-Third-Quarter-2021-Results.html Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast ClearPoint Neuro EPS misses by $0.02, beats on revenue https://seekingalpha.com/news/3768099-clearpoint-neuro-eps-misses-0_02-beats-on-revenue ClearPoint Neuro (NASDAQ:CLPT): Q3 GAAP EPS of -$0.18 misses by $0.02. Revenue of $4.6M (+30.7% Y/Y) beats by $0.6M.

Ach Umsatz und EPS sind hier relativ zweitrangig. Da geht's eher um FDA Approvals, Pipeline etc.

Hab das Gefühl das es morgen runtergeht da die Schätzungen verfehlt wurden 🙈 Hoffentlich täusche ich mich 😅

https://www.stocktitan.net/news/CLPT/clear-point-neuro-reports-second-quarter-2021-g1p8jrp7djsn.html Record Case Volume Supported Clinically During the Quarter Second Quarter Highlights • Reported revenue of $3.4 million, a 38% year-over-year increase; • Clinical team supported a record 249 cases, a 98% year-over- year increase; • Increased biologics and drug delivery revenue to $1.4 million, a 19% year-over-year increase; • Added biologics and drug delivery relationships bringing current count of active partners to approximately 35 from approximately 30 in Q1 2021; and • Announced FDA clearance of the SmartFrame Array and performed first human cases. Business Outlook • The Company continues to estimate total case volume supported to be in the range of 900 – 1000 for 2021; and • The Company continues to estimate revenue to be between $16.0 and $17.5 million for 2021. ...